Trade Name “Bank” Proposed For Neutral/Extreme Controls In FDA Pilot
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s proposal includes limited number of control names.
You may also be interested in...
FDA’s Trade Name Review Questioned At Public Meeting
Industry wonders whether its pilot submissions hold weight against agency evaluations.
FDA’s Drug Naming Pilot Moves Forward, But Industry May Need Sweeter Rewards
Firms lack explicit incentives to participate in the proposed self-evaluation, which will be discussed at a public meeting June 5-6.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.